Run time: 49m

  0      0

2019 AABB Annual Meeting On-Demand


TU3-24: New Paradigms in the Diagnosis and Treatment of Heparin Induced Thrombocytopenia (HIT)


Oct 22, 2019 11:00am ‐ Oct 22, 2019 12:30pm

Expiration Date: Dec 31, 2021


Credits: None available.

Standard: $25.00
Members: $20.00

Description

Heparin induced thrombocytopenia (HIT), a life-threatening, acquired pro-thrombotic condition, remains a diagnostic and therapeutic challenge. From a clinico-pathological perspective, newer approaches such as the HIT Expert Probability (HEP) score for ICU patients, and the PF4-dependent P-selectin expression assay appear to be improvements over previous diagnostic tools. In addition, newer approaches (encompassing the role of direct oral anticoagulants, IVIg, and therapeutic apheresis to the treatment of HIT will be discussed. The medical literature supporting these newer diagnostic and treatment approaches will be reviewed. In addition, this session will challenge participants to use these diagnostic and therapeutic approaches in a variety of clinical scenarios.

Learning Objectives:

  • Compare functional and antigenic assays as well as newer functional assays used in the diagnosis of HIT.
  • Construct algorithms that utilize clinical scoring and laboratory testing for the diagnosis of HIT.
  • Compare and contrast the risks and benefits of the use of direct oral anticoagulant, plasma exchange and IVIG in the treatment of HIT.

Please note: Anand Padmanabhan, MD, PHD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.

Speaker(s):

Chair(s):

  • Edward C. Wong, George Washington School of Medicine and Health Sciences; Children's National Health System; Quest Diagnostics Nichols Institute

Speaker(s):

Disclosures

  • Adam Cuker, MD, MS :

    Synergy: Consultant  I  Genzyme: Consultant  I  Kedrion: Consultant  I  Alexion: Grant/Research Support (Secondary Investigators need not disclose)  I  Bayer: Grant/Research Support (Secondary Investigators need not disclose)  I  Sanofi: Grant/Research Support (Secondary Investigators need not disclose)  I  Novo Nordisk: Grant/Research Support (Secondary Investigators need not disclose)  I  Pfizer: Grant/Research Support (Secondary Investigators need not disclose)  I  Takeda: Grant/Research Support (Secondary Investigators need not disclose)  I  Spark: Grant/Research Support (Secondary Investigators need not disclose)

  • Toyosi Onwuemene, MD, MS :

    Hemostasis and Thrombosis Research Society Grant Supported by funds from Shire: Grant/Research Support (Secondary Investigators need not disclose)

  • Anand Padmanabhan, MD, PHD :

    Veralox Therapeutics: Advisory Board  I  Retham Technologies: Stock Shareholder (self-managed)  I  Terumo BCT: Honoraria  I Janssen R&D: Consultant  I  GE Healthcare: Device support for Apheresis QI initiative

  • Edward Wong :

    Quest Diagnostics: Stock Shareholder (self-managed), Full-time/Part-time Employee  I  Comprehensive Care Services: Consultant

Credits Available


TU3-24: New Paradigms in the Diagnosis and Treatment of Heparin Induced Thrombocytopenia (HIT) Evaluation

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content